A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours

Richard Wilson, P. Hari Dass, Sandra Van Schaeybroeck, Elena Elez, A Quinton, R. Jones, Jennifer Houlden, Linda Collins, C Roberts, Sharon Love, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, alberto Bardelli, Pierre Laurent=puig, Tim Maughan, Josef Tabernero, Marc Peeters, Mark Middleton, Christian Rolfo

Research output: Contribution to journalMeeting abstractpeer-review

Fingerprint

Dive into the research topics of 'A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours'. Together they form a unique fingerprint.